nivolumab,ipilimumab,cabozantinib,sunitinib
exelixis,bms,pfizer
['lba443', 'gu ', '#603', 'urothelial', 'rcc,(-irccs),(-srcc),(-urcc)', 'urothelial carcinoma', 'renal,(-adrenal)', 'check,mate,274', 'check,mate,9er', 'cm274', 'scienceatbms', 'bms', 'bristol', 'exelixis']
#ascogu23 reminder- join us on 2/18 at 2.10pm pst,for oral presentation by on the 44-month median follow-up data from our checkmate -9er trial w/ comparing #immunotherapy + tki vs tki for 1l #arcc- #603 
Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below: